RecruitingPhase 4NCT07174349

Uroselective Alpha-1-Antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery

The Use of an Uroselective Alpha-1-antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery

Sponsor

Mayo Clinic

Enrollment

20 participants

Start Date

Oct 1, 2026

Study Type

INTERVENTIONAL

Conditions

Urinary Retention Postoperative

Summary

The purpose of this research is to see if the use of tamsulosin can decrease both the incidence and duration of urinary retention, as well as hospital length of stay following spine surgery.

Eligibility

Min Age: 35 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Placebo and a drug called Uroselective alpha-1-adrenergic receptor antagonist for people with urinary retention postoperative. The study is currently recruiting participants at 1 location. People eligible for this study include aged 35 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGUroselective alpha-1-adrenergic receptor antagonist

Subjects will receive Tamsulosin (0.4 mg daily) beginning 5 days prior to surgery and for the duration of the postoperative hospital stay (approximately 8-12 days)

OTHERPlacebo

Subjects will receive placebo beginning 5 days prior to surgery and for the duration of the postoperative hospital stay (approximately 8-12 days)